Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Research Article Volume 3 Issue 4

In silico Recombinant Vaccine Candidate Against Coronavirus (2019-nCoV)

Mostafa Norizadehtazehkand1* and Orkideh Hajipour2

1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Zonguldak Bulent Ecevit University, Zonguldak, Turkey
2Department of Biology, Institute of Basic and Applied Sciences, Pamukkale University, Denizli, Turkey

*Corresponding Author: Mostafa Norizadehtazehkand, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Zonguldak Bulent Ecevit University, Zonguldak, Turkey.

Received: February 06, 2020; Published: March 04, 2020



  Coronavirus (Wuhan Coronavirus) is a type of virus which has RNA and determined by club like spikes of its surface. The virus is a pathogen virus and it can be infected humans and other animals. This study was aimed to design and analysis of multi epitope vaccine against Wuhan Coronavirus by different bioinformatics analysis and software’s. The vaxiJen score of these sequences were 0.4052, 0.4201, and 0.4371. The result of Allg Pred and Toxinpred showed that the vaccine does not have allergenic or toxic effect for human cells. The result obtained from Protparam showed that the molecular weight of vaccine is 48.68 kDa. The estimated half-life of multi epitope based vaccine was found to be greater than 20 hours in mammalian cells, greater than 30 hours in yeast cells, and greater than 10 hours in E.coli and the candidate vaccine is stable and soluble in water. The membrane helices value of vaccine was 17.73%. Ramachandran plot analysis supported the high quality structure of the refined model. The result of protein protein docking showed the maximum affinity of candidate vaccine to HLA-A0201, HLA - B2705, HLA-B5704, and HLA - B57037 with the score of -686.54,-709.05, - 633.53, and 642.61 respectively. The result of this research showed that our designed vaccine maybe stimulate B-Cells and different types of T-cells. However, the vaccine could be produced (in lab scale) and tested in laboratory animals.

Keywords: B-Cell; MHC Class I; Multi Epitope; Recombinant Vaccine; Wuhan Coronavirus



  1. Fung TS and Liu DX. “Human coronavirus: host-pathogen interaction”. Annual Review of Microbiology 73 (2019): 529-557.
  2. Luk HKH., et al. “Molecular epidemiology, evolution and phylogeny of SARS coronavirus”. Infection, Genetics and Evolution (2019):  21-30.
  3. Ramadan N and Shaib H. “Middle East respiratory syndrome coronavirus (MERS-CoV): A review”. Germs 9 (2019): 35-42.
  4. Wu J T., et al. “Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study”. The Lancet (2020).
  5. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature (2020): 1-4. 
  6. Benvenuto D., et al. “The 2019 new Coronavirus epidemic: evidence for virus evolution”. Bio Rxiv (2020). 
  7. WHO. Novel Coronavirus – China. Archived from the original (2020).
  8. Operations Dashboard for ArcGIS (2020).
  9. Chan J FW., et al. “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster”. The Lancet (2020).
  10. Rothe C. “Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany”. NEJM: Correspondence to the Editor Page (2020).
  11. Srivastava S., et al. “Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach”. Infection and Drug Resistance 11 (2018): 2377-2391.
  12. Doytchinova IA and Flower DR. “VaxiJen: a server for prediction of protective antigens, tumor antigens and subunit vaccines”. BMC Bioinformatics 8 (2007): 4.
  13. Golshani M., et al. “In silico analysis of Shiga toxins (Stxs) to identify new potential vaccine targets for Shiga toxin-producing Escherichia coli”. In Silico Pharmacology 5.1 (2016): 2.
  14. Adhikari UK., et al. “Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus”. Journal of Immunology Research (2018): 6718083.
  15. Dhanda SK., et al. “Novel in silico tools for designing peptide-based subunit vaccines and immunotherapeutics”. Brief Bioin form 18.3 (2017): 467-478.
  16. Shey RA., et al. “In-silico design of a multiepitope vaccine candidate against onchocerciasis and related filarial diseases”. Scientific Reports 9 (2019): 4409.
  17. Khan A., et al. “Computational identification, characterization and validation of potential antigenic peptide vaccines from hrHPVs E6 proteins using immunoinformatics and computational systems biology approaches”. PLoS One 13.5 (2018): e0196484.
  18. Norizadehtazehkand M and Hajipour O. “In silico Design a vaccine Candidate against Corynebacterium diphtheria”. International Journal of Molecular and Clinical Microbiology 9.1 (2019): 1082-1089.
  19. Shahsavani N., et al. “In silico Homology Modeling and Epitope Prediction of NadA as a Potential Vaccine Candidate in Neisseria meningitides”. International Journal of Molecular and Cellular Medicine 7.1 (2018): 53-68.
  20. Norizadehtazehkand M and Hajipour O. “Multi Epitope Vaccine Candidate against Mycobacterium Tuberculosis”. Drug Designing and Intellectual Properties International Journal (DDIPIJ) (2019).
  21. Dar HA., et al. “Immunoinformatics-Aided Design and Evaluation of a Potential Multi-Epitope Vaccine against Klebsiella Pneumoniae”. Vaccines (Basel) 7.3 (2019): 88.


Citation: Mostafa Norizadehtazehkand and Orkideh Hajipour. “In silico Recombinant Vaccine Candidate Against Coronavirus (2019-nCoV)". Acta Scientific Microbiology 3.4 (2020): 17-23.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US